IDXX · every analyst question and management's answer
Nov 2, 2026 earnings call — Raised full-year revenue and diagnostics growth
Company raised full year revenue range to $4.741 billion to $4.767 billion and increased EPS outlook to $14.96 to $15.16.
Revenue $1.2B (est $1.2B) · EPS $3.96 (est $3.73)
Key quotes
"As low as $15 in the U.S., when run with most blood work panels in the IDEXX reference labs."
"Premium instrument placements reached 5.78 thousand units in the quarter and placement quality remained high."
"The ezyVet revenue run rate is approximately $20 million annualized and growing at strong double digit rates, creating another revenue growth driver for the software modality and opportunity for further supporting diagnostic utilization."
Analyst Q&A 7
Why growth is stronger than expected
Q (Christopher Schott · JPMorgan): They asked why organic growth is running closer to 10% versus the initial 8% guide and how much is from new platforms, salesforce expansion, or visit trends. They also asked how puppy and older-dog visit trends are evolving and implications for long-term visits.
A: Management said growth is volume-led and comes from innovations (InVue Dx, CancerDx, ProBNP, pancreatic lipase), strong commercial execution, and higher-quality visits driven by pet demographics. They said instrument placements and new lab customers are strong and that aging pets are a positive trend; growth does not rely on rising visit counts.
"Our growth is outpacing what we are seeing in terms of broader sector averages." — Michael Erickson (CEO)
Analyzer placements and margin impact
Q (Jonathan Block · Stifel): He asked how to think about the pace of analyzer placements versus the 20 thousand, 5-year target given fast early placements. He also asked whether Covet acquisition costs will dilute 2027 operating margin expansion and whether to prudently lower margin assumptions.
A: Management said demand for InVue Dx is strong worldwide and they are on track to exceed both the 5.5 thousand placement goal for the year and the 20 thousand five-year goal. They also said they included about 30 basis points of operating margin impact from the Covet acquisition across Q3 and Q4, have factored that into the profile, and expect to grow the total company revenues in line with longer-term expectations while integrating Covet.
"We are really pleased with the momentum and the demand for NVDX really around the world as I noted, we saw close to half our placements coming internationally." — Michael Erickson (CEO)
Macro sensitivity and RefLab growth
Q (Erin Wright · Morgan Stanley): She asked how much macro sensitivity they baked into guidance and whether demand shifted during the quarter, how that affects launching a new instrument next year, and how RefLab growth breaks down between market share gains versus higher utilization.
A: They said clinical visit trends have been consistent and are captured in the guide range, though quarter-to-quarter variability can occur. They said the strategic focus is on improving visit quality by broadening diagnostic use; reference lab growth is global, driven by long-term investments in networks, technology, and new tests like CancerDx, and they are seeing strong new-customer growth and product-led utilization.
"What we are really excited by is the, you know, continued quality of the visits, and that is really what we are focused on is driving that quality." — Andrew Emerson (CFO)
InVue Dx demand and Multi-Q event
Q (Goldman Sachs): He asked what drove strong InVue Dx placements and how clinics use it across ear, blood, or FNA. He also asked what they will disclose at VMX about Multi-Q and the expected launch timing.
A: They said InVue Dx fills a long-standing need in cytology by removing the slide and using advanced optics and AI, and the instrument's expanding menu (blood morphology and early FNA) increases clinical value and demand. They said placements were strong globally (almost half international) and they will discuss MultiQDX at the Orlando event but gave no further launch details today.
"It takes out the slide, which is a revolutionary step." — Michael Erickson (CEO)
Recurring CancerDx customers
Q (KeyBanc): He asked how many of the clinics that ordered CancerDx are recurring users versus one-time users.
A: They said CancerDx has strong customer momentum but they do not break out recurring versus one-time customers. They reported they are at over 14 thousand customers who have ordered and run CancerDx and noted 70% of CancerDx runs are done together with blood work in their reference lab.
"We are at over 14 thousand customers having ordered and run CancerDx." — Michael Erickson (CEO)
ARR per InVue Dx and global rollout
Q (Daniel Clark · Leerink Partners): He asked how revenue per InVue Dx analyzer is trending given the $3.5 thousand to $5.5 thousand range and the rollout of FNA, and how to think about incremental placement upside domestically versus internationally.
A: They said they are comfortably within the $3.5 thousand to $5.1 thousand annual recurring revenue range per instrument and that this range covers ear cytology, blood morphology, and FNA. They said rolling out fine needle aspirate gives upside while expanding internationally and that they are in full worldwide launch mode with InVue Dx and see meaningful headroom for placements.
"So we are comfortably in the range of the $3.5 thousand to $5.1 thousand annual recurring revenue per instrument that we have shared in the past." — Michael Erickson (CEO)
pricing resilience and new test feedback
Q (BNP Paribas): She asked whether diagnostics pricing will remain resilient versus animal pharma pricing actions and whether IDEXX expects diagnostics to be isolated. She also asked for early feedback on the mast cell tumor addition to CancerDx.
A: They said they focus pricing on the value they create and are transparent about how price factors into growth, using examples like $15 CancerDx screening in the U.S. to expand access and drive volume. They said pricing expectations have been consistent and unchanged, and that mast cell tumor addition is getting very positive early feedback, with hemangiosarcoma coming next.
"We focus on price as a measure of the value that we are creating." — Michael Erickson (CEO)
Aug 4, 2026 earnings call — inVue Dx and Cancer Dx drive growth
Company raised full-year revenue outlook to $4,700 million to $4,745 million and EPS to $14.69 to $14.94.
Revenue $1.2B (est $1.2B) · EPS $4.27 (est $3.94)
Key quotes
"inVue Dx momentum continues to be strong. We placed 2,700 instruments through the first half and are on pace to achieve our full year placement goal."
"IDEXX Cancer Dx reached another milestone, surpassing 10,000 global clinics ordering since launch, a reflection of how this test is addressing the critical need for early cancer detection and becoming part of routine veterinary care."
"We're updating our full year revenue range to $4,700 million to $4,745 million, an increase of $5 million at midpoint, net of a $20 million increase in operational performance, offset by a $15 million headwind from updated foreign currency effects."
Analyst Q&A 7
FNA rollout and supplies revenue
Q (Erin Wilson Wright · Morgan Stanley): Analyst asked how the FNA rollout is progressing, whether it is boosting inVue placements, and how consumables revenue is tracking versus expectations. They also asked about Reference Lab growth and how visit trends affect long-term growth.
A: Management said consumable revenue per inVue Dx instrument is within the $3,500 to $5,500 range and the inVue rollout has been outstanding with 2,700 placements in the first half and 9,000 overall. FNA is progressing on schedule through a controlled launch, with planned full availability by the end of the year, and early results show more masses being examined. They also said lab growth reflects new tests, commercial execution and conversions worldwide.
"And based on the great feedback that we're getting from customers, we're broadening that again meaningfully as we go into Q3 with planned full availability by the end of the year." — Michael Erickson (CEO)
Vet visit differences and wellness visits
Q (Christopher Schott · JPMorgan): Analyst asked if visit trends differ by corporate vs independent or urban vs suburban practices, and what will be needed to get wellness visits growing again.
A: Management said they do not see material differences across geography or corporate versus independent practices. They emphasized focusing on 'visit quality' — more diagnostics per visit — and said there is large headroom because only about 1 out of 10 U.S. wellness visits get bloodwork today. They expect innovation and commercial work to raise diagnostic use in wellness visits over time.
"I think the key is and what we really focus on is, visit quality." — Michael Erickson (CEO)
International investments and sales growth
Q (Jonathan Block · Stifel): Analyst asked why IDEXX is adding another tranche of commercial investment now, whether it targets different international markets, and if it supports multiple innovations. They also asked what is driving the stronger CAG Diagnostics recurring growth outlook.
A: Management said they are focused on international opportunity and have been investing to expand field presence, labs, software and product adaptations for local needs. They said close customer work increases adoption and flow-through, and 40% of inVue Dx placements are already international. They also pointed to recent and upcoming product launches as support for stronger recurring growth.
"We're just really excited about the opportunity internationally." — Michael Erickson (CEO)
SDMA on Catalyst and Cancer Dx
Q (Ryan Daniels · William Blair): Analyst asked if adding SDMA to the Catalyst will cannibalize the reference lab. They also asked about expectations for expanding the Cancer Dx panel and how that could affect lab growth and market share.
A: Management said adding SDMA at the point of care does not reduce lab testing; instead testing at one modality drives more overall diagnostics. They explained SDMA helps detect more renal dysfunction in sick pets and has long been included in lab panels, so the point-of-care slide simply streamlines clinic workflow. For Cancer Dx, they expect adding mast cell tumor detection will make the panel more valuable and pair well with inVue Dx for follow-up, helping sector growth and conversions from competitors.
"What we consistently see, Ryan, is whenever we invest into one modality, for example, at the point of care or vice versa, the reference labs, we actually see that testing begets testing and we drive overall more diagnostics." — Michael Erickson (CEO)
U.S. vs international growth mix
Q (Daniel Christopher Clark · Leerink Partners): Analyst asked how second-half CAG growth is expected to split between the U.S. and international given strong ex-U.S. performance. They also asked if the 5+ age pet cohort trend is changing quarter to quarter.
A: Management said both U.S. and international regions show strong momentum, with international multiple quarters of double-digit growth and continued opportunity there. They noted clinical visit challenges are more of a U.S. constraint, but diagnostics growth in the U.S. has been ramping. On the 5+ pet cohort, they said the trend is generally positive and consistent across multiple quarters.
"Overall, on the U.S. side, certainly, the clinical visit challenges that we've seen have been the key constraining factor." — Andrew Emerson (CFO)
inVue placements and launching platforms
Q (Michael Ryskin · BofA): Analyst asked whether the ~1,600 inVue placements this quarter are normal lumpiness or related to FNA rollout, and whether IDEXX can launch two platforms (e.g., Multi-Q) at once given current capacity.
A: Management said placements vary because customers take instruments when they are ready and they work in partnership with them; year-to-date there were about 2,700 placements, roughly 50% of the company target. They said Q4 is typically a stronger capital quarter and they are comfortable with commercial capacity to launch and support multiple platforms simultaneously.
"That puts us essentially 50% of the way towards the full year delivery." — Andrew Emerson (CFO)
Margins, investments, cash use choices
Q (Daniel Grosslight · Citi): Analyst asked for more detail on second-half margin degradation, timing of incremental investments across Q3 and Q4, and how IDEXX balances buybacks versus M&A.
A: Management said gross margins should lead operating margins and that strong recurring revenue supports high incremental margins; they will continue incremental investments in commercial, R&D, IT and AI through the second half. They noted Q3 should see a comparable 20 to 50 basis points operating margin benefit, they assess M&A opportunistically while prioritizing organic growth, and they have used buybacks to return excess cash so far.
"Here, we did highlight on a comparable basis in Q3, we expect 20 to 50 basis points of operating margin benefit in Q3" — Andrew Emerson (CFO)
AI-generated notes on the earnings call transcript. Quotes are taken from the transcript. This is not a FolioObs investment view.